Securities code: 688321 securities abbreviation: Shenzhen Chipscreen Biosciences Co.Ltd(688321) Announcement No.: 2022-005 Shenzhen Chipscreen Biosciences Co.Ltd(688321)
Announcement on receiving the implementation letter of the opinions of the audit center on the issuance of convertible corporate bonds by Shenzhen Shenzhen Chipscreen Biosciences Co.Ltd(688321) Technology Co., Ltd. to unspecified objects from Shanghai Stock Exchange
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear legal liabilities for the authenticity, accuracy and integrity of its contents according to law.
Shenzhen Chipscreen Biosciences Co.Ltd(688321) (hereinafter referred to as the “company”) received the letter of implementation of the opinions of the audit center on Shenzhen Chipscreen Biosciences Co.Ltd(688321) issuing convertible corporate bonds to unspecified objects (szkss (refinancing) [2022] No. 8) (hereinafter referred to as the “implementation letter”) issued by the Audit Center for listing on the science and Innovation Board of Shanghai Stock Exchange (hereinafter referred to as the “Audit Center of Shanghai Stock Exchange”) on January 13, 2022 。 The audit center of Shanghai Stock Exchange reviewed the application documents submitted by the company for issuing convertible bonds to unspecified objects, and formed audit opinions and problems to be implemented.
The company will, in accordance with the requirements of the above implementation letter, implement the relevant issues one by one, disclose the reply in the form of temporary announcement, and timely supplement and submit the relevant recommendation working papers within the specified time limit after the disclosure of the reply.
The issue of the company can be implemented only after it has passed the examination of the Shanghai Stock Exchange and the decision of consent to registration made by the China Securities Regulatory Commission (hereinafter referred to as the “CSRC”). There is still uncertainty about whether the issuance can finally pass the examination of Shanghai Stock Exchange and obtain the consent of China Securities Regulatory Commission for registration. The company will timely perform the obligation of information disclosure in strict accordance with the requirements of relevant laws and regulations and according to the progress of this issuance. Please pay attention to the investment risks.
It is hereby announced.
Shenzhen Chipscreen Biosciences Co.Ltd(688321) board of directors January 14, 2022
